Search PubMed⌕ Search

Biomedical subjects

M Santana

Publications and source records attributed to M Santana.

25 records · Page 2Linked to original sources
PubMed1983

Control of experimental massive periretinal proliferation by daunomycin: dose-response relation.

A condition similar to massive periretinal proliferation in man can be produced in rabbits by injecting homologous fibroblasts into the vitreous. We have studied the effect of daunomycin, a cytotoxic drug, in this model to determine a dose which would not be toxic to the retina but would be effective in preventing proliferation of the injected fibroblasts and eventual retinal detachment. The results of this study demonstrate that daunomycin at a dose of 9 nmol per eye reduces the incidence of retinal detachment by over 50%. Doses higher than 30 nmol per eye are toxic to the retina.

Animals↗
PubMedDate not supplied

Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy.

We used an experimental model of proliferative vitreoretinopathy (PVR) and cell-induced traction retinal detachment to study the therapeutic value of six cytotoxic drugs (actinomycin C, colchicine, cytosine arabinoside hydrochloride, 5-fluorodeoxyuridine, vinblastine sulfate, and daunomycin). Pigmented rabbits were injected with 2.5 X 10(5) cultured homologous dermal fibroblasts. At the same time, cytotoxic drugs were injected into the vitreous in an attempt to inhibit cellular proliferation. The sensitivity of the cells to the drug was also tested in vitro before injection. Daunomycin at a dose of 10 nmol per eye stopped cellular proliferation and subsequent traction retinal detachment in vivo. The electroretinogram (ERG) showed no evidence of drug-induced retinal toxicity with this dose of daunomycin. No alteration in frequency or severity of vitreal membranes and retinal detachment was observed after injection of equivalent doses of the other drugs.

Animals↗
PubMedDate not supplied

[Effectiveness of postoperative autologous blood transfusion after knee replacement surgery and influence of preoperative hemoglobin level].

OBJECTIVE: To evaluate the effectiveness of postoperative autologous blood transfusion on reducing the need for allogenic transfusion during recovery from total knee arthroplasty until hospital discharge, and to determine whether effectiveness is related to preoperative hemoglobin level. MATERIAL AND METHODS: Retrospective study of patients undergoing surgery at Hospital Jerez de la Frontera, Spain, in 2003, assessing the association between postoperative autologous blood transfusion, preoperative hemoglobin, and allogenic transfusion requirements. RESULTS: A total of 107 patients were studied. Eighty-three received autologous blood transfusions after surgery and 15 (14.02%) required allogenic transfusion. The rate of allogenic transfusion was higher in association with hemoglobin levels exceeding 13 g x dL(-1) (P=0.003) and it was lower in patients who received autologous blood transfusions (P=0.046). In patients who received autologous transfusion, preoperative hemoglobin level and risk of allogenic transfusion were unrelated. When autologous transfusion was not given, allogenic transfusion risk was higher when hemoglobin concentration was less than 13 g x dL(-1) (P=0.0008). Autologous transfusion had a significant effect when hemoglobin level was less than 13 g x dL(-1) (P=0.002) but did not affect the rate of transfusion when hemoglobin was 13 g x dL(-1) or more. CONCLUSIONS: Autologous blood transfusion is effective for reducing the need for allogenic transfusion after knee replacement surgery, particulary when a patient's hemoglobin level is less than 13 g x dL(-1).

Aged↗
PubMedDate not supplied

[Intravenous diltiazem in the reversion to sinus rhythm in supraventricular tachyarrhythmias].

UNLABELLED: The safety and therapeutic efficacy (sinus rythm recovery) of intravenous diltiazem vs verapamil in paroxysmal supraventricular tachycardias (PSVT), and diltiazem vs the Sokolow protocol (i.v. digital and oral quinidine) in recent onset atrial fibrillation (AF) were compared. Sixty patients with PSVT were randomized to have a bolus of 0.3 mg/Kg of diltiazem or 75 micrograms/Kg of verapamil. If after 15 minutes the PSVT persisted, a 6 hours i.v. infusion of diltiazem was started (0.0028 mg/Kg/min) or a second dose of verapamil was repeated. In 100 patients with PAF the alternative to diltiazem was i.v. digital plus oral quinidine (400 to 1,200 mg). Ninety per cent of the PSVT and 64% of de AF, recovered sinus rythm with diltiazem. The same results were obtained with verapamil in PSVT. With the Sokolow protocol 90% of the AF recovered sinus rythm. In 83% of AF who did not revert to sinus rythm, diltiazem was effective for slowing the ventricular response. In relation with the drug safety, only 5 patients showed hypotension, without clinical relevance, in the diltiazem group. With verapamil one patient had a transitory ischemic attack after recover sinus rythm. In the Sokolow group 26% had minor gastrointestinal disorders. CONCLUSIONS: In this clinical trial (n = 160): 1) Diltiazem and verapamil were highly and equally effective (90%) in reverting PSVT to sinus rythm. 2) The Sokolow protocol was more effective than diltiazem for reversing PAF to sinus rythm (90% vs 64%, p < 0.01). 3) Diltiazem was effective for slowing the ventricular rate in 83% of the patients with AF who did not revert to sinus rythm. 4) There was a low incidence of side effects with diltiazem and verapamil. 5) Diltiazem is a first choice therapeutic agent in reverting PSVT to sinus rythm and for slowing the ventricular rate in AF.

Adult↗